Subscription of warrants in Qlife Holding AB series TO 1 commences today, May 3, 2021

Today, May 3, 2021, the subscription period of the warrants series TO 1 begins. The warrants were issued in connection with Qlife Holding AB's ("Qlife" or the "Company") issue of units in February 2020.

The subscription period runs from 3 May 2021 until 31 May 2021. Two (2) warrants entitle to subscription of one (1) new share in the Company at a price of SEK 17.50 per share. If all warrants are exercised, Qlife will receive approximately SEK 39.1 million before issuance costs amounting to approximately SEK 1.4 million. In order for the warrants not to expire without value, the holder must actively exercise his warrants for subscription of shares no later than 31 May 2021 or sell the warrants no later than 27 May 2021.

Summary of the listing options:

Subscription period:                3 - 31 May 2021.

Last trading day for TO1:       27 May 2021.

Terms:                                      Two (2) warrants entitle to subscription of one (1) new share.

Subscription price:                  SEK 17.50 per share, no commission fee.

Issue volume:                          4,472,600 warrants series TO1. Upon full subscription, Qlife will receive a total of approximately SEK 39.1 million before issuance costs.

Please note that warrants series TO1 that are not disposed of no later than 27 May 2021 or exercised no later than 31 May 2021 will expire worthless.

Full terms and conditions for warrants series TO1 are available on the Company's website (www.qlifeholding.com).

How the warrants are exercised:

If you have your warrants nominee registered

If the option holder has his warrants in a securities custody account with a bank or other nominee, in an investment savings account or endowment account (nominee-registered ownership), subscription and payment shall be made to the respective bank or nominee who instructs on further instructions regarding the procedures for using their warrants.

For more information and for further instructions on how to exercise your warrants, please contact your nominee in due time. Please note that the bank/nominee needs your notification of use of the warrants well in advance of the subscription period.

If you have your warrants directly registered (VP account)

A registration form is available on Nordic Issuing (www.nordic-issuing.se), and Qlife's (www.qlifeholding.com) respective websites. Subscription must be made by immediate cash payment according to instructions on the application form. The application form and proceeds must be provided to Nordic Issuing no later than the date indicated on the application form.

As soon as both subscription and payment have been registered with Nordic Issuing, the warrants are replaced with interim shares pending registration with the Swedish Companies Registration Office.

For questions regarding warrants of series TO1, please contact

Nordic Issuing

Tel: +46 (0)40-632 00 20

Email: info@nordic-issuing.se

IMPORTANT INFORMATION

The information in this press release neither contains nor constitutes an offer to raise, subscribe for or otherwise trade in shares, warrants or other securities in Qlife. The invitation to interested persons to subscribe for units consisting of shares and warrants TO1 Qlife has only been made through the prospectus published by Qlife on 17 January 2021.

Mette Gross, Chair Qlife Holding AB

E-mail: mette.gross@lehdab.com

Tel. No.: +46 (0)73-517 85 25

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

Subscribe

Documents & Links